PARATEK GETS PATENT FOR REDUCING MICROBIAL RESISTANCE TO
DRUGS.
Paratek Pharmaceuticals, Inc., Boston, has announced the issuance
of U.S. Patent No. 6,346,391, entitled "Methods of Reducing
Microbial Resistance to Drugs." The patent covers methods . . .
CERETEK AWARDED SBIR GRANT FOR CANCER DRUG DISCOVERY.
Ceretek has been awarded a Small Business Innovation Research
(SBIR) Phase I grant from the National Cancer Institute (NCI).
The $100,000 grant will be used by Ceretek to advance certain
cancer . . .
VIACELL TO USE STEM CELLS TO DEVELOP NEW DIABETES
TREATMENTS.
ViaCell, Inc., Boston, Mass., a clinical-stage biotechnology
company focused on the development of cellular therapies, in conjunction
with its ViaCell Endocrine Science subsidiary, will expand . . .
REGENERON INITIATES PHASE II CLINICAL TRIAL OF IL1 TRAP.
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), Tarrytown, N.Y.,
has initiated a dose-ranging Phase II trial to study the safety and
efficacy of the Interleukin-1 (IL1) Trap in patients with . . .
EXACT SCIENCES/LABCORP TO OFFER NON-INVASIVE COLORECTAL
TEST.
EXACT Sciences Corporation (NASDAQ: EXAS), and Laboratory
Corporation of America Holdings (NYSE:LH) (LabCorp) have formed an
exclusive, long-term strategic partnership to commercialize . . .
CERUS EXPANDS PATENT COVERAGE FOR PATHOGEN INACTIVATION.
Cerus Corporation (Nasdaq:CERS), Concord, Calif., has announced
that the U.S. Patent and Trademark Office has issued a patent to Cerus
that expands its patent coverage for methods to inactivate . . .
AVANT GETS PATENT FOR CHOLESTEROL MANAGEMENT VACCINE.
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN), Needham, Mass., has
announced that the United States Patent and Trademark Office has issued
U.S. patent 6,410,022 to the company covering AVANT's . . .
NATIONAL CANCER INSTITUTE TO CONDUCT DIMERICINE CLINICAL
TRIAL.
Daniel B. Yarosh, Ph.D., president and chairman of Applied Genetics
Inc. Dermatics (AGI), Freeport, N.Y., has announced that the National
Cancer Institute intends to conduct a one-year clinical . . .
INOSINE IMPROVES FUNCTION IN ANIMALS AFTER STROKE.
A new study indicates that Inosine, a naturally occurring chemical,
can induce axon (nerve fiber) growth within the brain and spinal cord,
and thereby improve motor function after stroke in animal . . .
LAWRENCE LIVERMORE FINDS UNIQUE ANTHRAX DNA SIGNATURES.
Scientists from Lawrence Livermore National Laboratory, Salt Lake
City, with collaborators at Northern Arizona University and Los Alamos
National Laboratory, have discovered new DNA regions unique . . .
NEW CLASS OF CYCLOSPORIN ANALOGS ARE ANTI-INFLAMMATORY.
Enanta Pharmaceuticals Inc., Watertown, Mass., has discovered a new
class of cyclosporin analogs targeted to the treatment of asthma. These
compounds can be delivered topically to the target organ . . .
MILLENNIUM'S MLN341 EFFECTIVE AGAINST MULTIPLE
MYELOMA.
Millennium Pharmaceuticals Inc. (Nasdaq: MLNM), Cambridge, Mass.,
has announced updated preliminary findings of a phase II clinical trial
of its investigational drug MLN341 (formerly known as . . .
MICROISLET ADDS NEW PATENT FOR ENCAPSULATION OF ISLET
CELLS.
MicroIslet, Inc. (OTC Bulletin Board: MIIS), San Diego, Calif., has
announced that the United States Patent Office has granted patent number
6,365,385, which is licensed exclusively to the company . . .
INTERLEUKIN MAPS NOVEL SNP FOR KEY INFLAMMATION GENE.
Interleukin Genetics, Inc. (NASDAQ:ILGN), Waltham, Mass., has
reached a significant milestone in its inflammation research program
with the completion of a comprehensive SNP (Single . . .
DENDREON GETS ORPHAN DRUG STATUS FROM FDA FOR MYLOVENGE.
Dendreon Corporation (Nasdaq:DNDN), Seattle, has announced that its
therapeutic vaccine for multiple myeloma, Mylovenge(TM), has been
granted orphan drug status by the FDA.
Orphan drug . . .
HOLLIS-EDEN REPORTS HE2500 REDUCES PARALYSIS FROM EAE.
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) has announced data
from a preclinical study demonstrating that HE2500, an investigational
immune regulating hormone, significantly reduces ongoing . . .
GENEFORMATICS AIDS INCYTE ANNOTATE PROTEIN SEQUENCE
FUNCTIONS.
GeneFormatics Inc. and Incyte Genomics Inc. (Nasdaq:INCY) have
entered into a collaborative research agreement. Under the terms of the
agreement, GeneFormatics will use its proprietary and . . .
BIOMARIN INITIATES PHASE 2 CLINICAL TRIAL OF ARYPLASE.
BioMarin Pharmaceutical Inc. (Nasdaq and Swiss SWX New Market:
BMRN), Novato, Calif. has begun dosing patients in a Phase 2 clinical
trial of Aryplase (recombinant human N-acetylgalactosamine . . .
LARGE SCALE BIOLOGY ISSUED PATENT FOR NEW PLANT SPECIES.
Large Scale Biology Corp. (Nasdaq:LSBC), Vacaville, Calif., has
been issued U.S. Patent 6,344,597 covering a fundamentally new plant
species designated Nicotiana excelsiana. The patent relates to . . .
KOSAN GETS SBIR GRANT FOR PRODUCTION OF POLYKETIDES.
Kosan Biosciences Incorporated (NASDAQ:KOSN), Hayward, Calif., has
been awarded a $230,000 Phase I Small Business Innovative Research
(SBIR) grant from the National Institute of Allergy and . . .
|
|